Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior Pharmaceuticals, Inc. (INDV) has filed an amended Form S-4 to register common stock to be issued in an all-stock merger of equals with Supernus Pharmaceuticals, Inc. Each outstanding Supernus share will be converted into the right to receive 1.5401 Indivior Shares, plus cash in lieu of fractional shares. Supernus will become a wholly owned subsidiary of Indivior, which will be renamed Supernus, Inc., and the combined company’s shares will trade on Nasdaq Global Select Market under the ticker “SUPN.”
Prior to closing, Indivior plans to declare a $1.0 billion Special Dividend for existing Indivior stockholders and certain equity award holders, payable only if the merger closes. In an “Alternative Dividend Scenario” if committed financing is unavailable, the dividend would instead total $1.0295 billion through a $500 million cash payment and $529.5 million in dividend payment rights. After the merger, Indivior stockholders are expected to own about 56.5% of the combined company on a fully diluted basis, with former Supernus holders owning about 43.5%, subject to customary closing conditions, regulatory approvals and stockholder votes at both companies’ special meetings on October 15, 2026.
Indivior Pharmaceuticals, Inc. (INDV) has filed an S-4 describing an all-stock merger of equals with Supernus Pharmaceuticals, Inc.. Artemis Merger Sub Inc., a wholly owned Indivior subsidiary, will merge into Supernus, which will become a wholly owned subsidiary of Indivior. Each Supernus share will be converted into 1.5401 Indivior Shares, with cash paid in lieu of fractional shares. After closing, Indivior will be renamed Supernus, Inc. and its common stock will trade on Nasdaq Global Select Market under the symbol SUPN.
Based on current fully diluted counts, former Indivior holders are expected to own approximately 56.5% and former Supernus holders approximately 43.5% of the combined company. Prior to effectiveness and subject to closing, Indivior will declare a $1,000,000,000 Special Dividend to its stockholders and certain equity award holders, payable after the merger, contingent on completion. Indivior has a $650 million committed term loan facility to help fund this dividend, and an Alternative Dividend structure (including a reduced $500 million cash dividend plus $529.5 million in dividend payment rights) if that financing is unavailable under defined conditions.
Indivior Pharmaceuticals, Inc. (INDV) reported that Chief Accounting Officer Anderson Woodrow D purchased 1,500 shares of its Common Stock on August 27, 2026 in an open market or private transaction at a price of $35.69 per share. Following this transaction, he directly owns 27,638 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. is the subject of an amended Schedule 13D in which several Oaktree-managed funds report a reduced position. The group now beneficially owns 909,053 shares of common stock on an as-converted basis, representing 0.76% of Indivior’s outstanding shares.
The position is held through $37.872 million principal amount of the Issuer’s 0.625% Convertible Senior Notes due 2031, convertible into common stock at an approximate conversion rate of $41.66 per share. Indivior had 118,013,649 shares outstanding as of July 28, 2026.
Within 60 days before this amendment, the Oaktree entities executed substantial open-market sales of Indivior common stock, including a sale of 4,542,968 shares at $37.75 on August 12, 2026, and multiple smaller trades. They also traded the convertible notes in the open market. As a result of these transactions through August 10, 2026, the group ceased to be a beneficial owner of more than five percent of Indivior’s common stock. Additional sales on August 11, 2026 triggered a material ownership change, and this amendment serves as an exit filing by the reporting persons.
Indivior Pharmaceuticals, Inc. reports that Chief Accounting Officer Anderson Woodrow D purchased 1,500 shares of common stock on 2026-08-05 at $36.28 per share in an open-market or private transaction. Following this buy, he directly owns 26,138 shares of the company’s common stock.
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have agreed to a tax-free, 100% stock-for-stock merger of equals to create a diversified CNS biopharmaceutical company. Supernus shareholders will receive 1.5401 Indivior shares for each Supernus share, with post-close ownership at 56.5% Indivior shareholders and 43.5% Supernus shareholders.
Before closing, Indivior will declare a special cash dividend of $1B in aggregate to its pre-closing stockholders, funded in part by an assumed additional $650m of debt. The combined company, to be named Supernus, Inc. and headquartered in Rockville, Maryland, is projected to have pro forma net revenue of $2,162m and Adjusted EBITDA of $888m for the twelve months ended June 30, 2026, implying a 41% Adjusted EBITDA margin and pro forma net leverage of 0.99x. Management targets at least $125m in annual cost synergies, with a commercial portfolio of 11 CNS medicines across four key therapeutic areas. Closing is targeted for Q4 2026, subject to shareholder and regulatory approvals and customary conditions.
Indivior Pharmaceuticals plans a merger of equals with Supernus Pharmaceuticals under an Agreement and Plan of Merger dated August 1, 2026. The combination is structured as a 100% tax-free stock-for-stock merger, with Supernus shareholders receiving 1.5401 Indivior shares for each Supernus share.
Indivior intends to declare a pre‑closing $1 billion aggregate dividend to existing stockholders. After closing, Indivior shareholders are expected to own 56.5% of the combined company and Supernus shareholders 43.5%. The merged business, to be named Supernus, Inc. and headquartered in Rockville, Maryland, would create a diversified CNS biopharmaceutical group with pro forma $2,162 million net revenue and $888 million Adjusted EBITDA for the twelve months ended June 30, 2026, including at least $125 million of expected annual cost synergies and a pro forma net leverage ratio of 0.99x. Closing is targeted for Q4 2026, subject to shareholder and regulatory approvals and other customary conditions.
Indivior Pharmaceuticals, Inc. reported strong results for the quarter ended June 30, 2026 and raised its full-year 2026 outlook. Q2 net revenue was $343 million, up 14% year over year, driven mainly by SUBLOCADE, whose total net revenue reached $253 million, up 21%.
GAAP net income for Q2 was $122 million, with non-GAAP net income of $142 million. Adjusted EBITDA rose to a record $186 million, an increase of 111% year over year, and Q2 non-GAAP operating expenses declined 33% versus the prior-year quarter.
For full-year 2026, the company now guides to total net revenue of $1,295–$1,365 million, SUBLOCADE net revenue of $1,010–$1,050 million, and adjusted EBITDA of $700–$740 million, while keeping non-GAAP operating expenses at $430–$450 million. Indivior repurchased approximately 4.7 million shares in Q2 for $175 million and expects about $420 million in 2026 cash flow from operations. Management also highlights a proposed merger with Supernus, expected to close in the fourth quarter of 2026, to build a diversified CNS biopharmaceutical business.
Indivior Pharmaceuticals, Inc. reported strong results for the quarter ended June 30, 2026, with total net revenue of $343 million, up 14% year over year, and record total SUBLOCADE net revenue of $253 million, up 21%. GAAP net income reached a record $122 million, while non-GAAP net income was $142 million.
Adjusted EBITDA rose to a record $186 million, up 111% year over year, with an adjusted EBITDA margin of 54% versus 29% a year earlier, reflecting higher SUBLOCADE volumes and lower non-GAAP operating expenses. US SUBLOCADE demand remained robust, with strong dispense unit growth and an estimated 76% share of the US long-acting injectable category.
Management raised full-year 2026 guidance, now expecting total net revenue of $1,295–$1,365 million, total SUBLOCADE net revenue of $1,010–$1,050 million, and adjusted EBITDA of $700–$740 million, with non-GAAP operating expenses unchanged at $430–$450 million. The company repurchased approximately 4.7 million shares in the quarter for $175 million and highlighted an expected ~$420 million of 2026 cash flow from operations, while continuing to pursue a proposed merger with Supernus expected in the fourth quarter.